{"id":"W4402565458","doi":"10.1016/j.annonc.2024.08.2267","title":"LBA28 ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; PharmaMar; Eisai; Natera; Chugai Pharmaceutical; Seagen; Incyte; BeiGene; Clovis Oncology; Novocure; Daiichi Sankyo Europe; Sanofi; Exelixis; Regeneron Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Placebo; Pembrolizumab; Radiation therapy; Chemotherapy; Adjuvant; Oncology; Internal medicine; Surgery; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001410777,0.001304179,0.002092184,0.0005436455,0.0003950009,0.001041785,0.001055773,0.00129825,0.006003977],"category_scores_gemma":[0.0006533384,0.0005627807,0.001513015,0.0003819795,0.0008172484,0.0007876694,0.0003063059,0.003963904,0.001258162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008210103,"about_ca_system_score_gemma":0.001400702,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002135385,"about_ca_topic_score_gemma":0.006721525,"domain_scores_codex":[0.9997101,0.0001345078,0.00001000165,0.00004217718,0.00002311864,0.00007997534],"domain_scores_gemma":[0.9996781,0.00006234229,0.00004704147,0.00002182081,0.00001988244,0.0001707022],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6989045,0.06227852,0.002494737,0.002305293,0.002732913,0.0001840613,0.0002568557,0.00264452,0.04099131,0.0007500381,0.008608132,0.1778491],"study_design_scores_gemma":[0.7183658,0.2656379,0.006030957,0.00009961676,0.0009513093,0.0001331043,0.00009484218,0.001168943,0.002552038,0.0002232051,0.00470319,0.00003901707],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9692307,0.01434212,0.001015831,0.001494588,0.0007750521,0.003172862,0.002204285,0.0003612993,0.00740329],"genre_scores_gemma":[0.9733657,0.008093187,0.002197674,0.001870234,0.0003313354,0.002407655,0.002740144,0.00006681415,0.008927213],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006003977,"threshold_uncertainty_score":0.02008528,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04039741290159089,"score_gpt":0.3819973967675289,"score_spread":0.341599983865938,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}